Assigned to HHS FOR COMMITTEE
ARIZONA STATE SENATE
Fifty-Sixth Legislature, Second Regular Session
FACT SHEET FOR H.B. 2582
pharmacists; collaborative practice agreements
Purpose
Expands the definition of provider, as it applies to collaborative practice agreements
between pharmacists and health care providers, to include certified nurse midwives and physician
assistants.
Background
Statute authorizes pharmacists to enter into collaborative practice agreements with
providers to initiate, monitor and modify drug therapy or provide disease management assistance.
Collaborative practice agreements may be between one or more pharmacists and one or more
providers and must: 1) outline the duties related to drug therapy and disease management that a
provider is delegating to a pharmacist to perform; 2) outline the eligible group of patients that may
be treated under the agreement; 3) specify, at minimum, the conditions to be managed by the
pharmacist, the circumstances for which the pharmacist must notify the provider and any
documentation or recordkeeping requirements; and 4) specify that the pharmacist must follow the
written guidelines provided by the provider and may provide drug therapy and disease
management services only pursuant to those guidelines. These guidelines must specify, at
minimum, the: 1) specific drugs or drug classes and conditions to be managed by the pharmacist;
2) conditions and events for which the pharmacist must notify the provider; and 3) laboratory tests
the pharmacist may order.
Provider means a licensed doctor of medicine, doctor of osteopathic medicine or registered
nurse practitioner (A.R.S. ยง 32-1970).
There is no anticipated fiscal impact to the state General Fund associated with this
legislation.
Provisions
1. Expands the definition of provider, as it applies to collaborative practice agreements between
pharmacists and health care providers, to include certified nurse midwives and physician
assistants.
2. Becomes effective on the general effective date.
House Action
HHS 2/15/24 DP 7-3-0-0
3
RD
Read 2/29/24 55-4-0-0-1
Prepared by Senate Research
March 15, 2024
MM/DM/slp